Lower CagriSema Doses Beat Placebo; Early Response Matters
Results from the phase 3 REDFINE 9 trial show that a lower dose of CagriSema is superior to placebo, which could give clinicians more flexibility with treatment.
Ähnliche Seiten
New Obesity Drugs Challenge Clinicians to Stay Up to Date